Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

VIVA2 Expansion: ten23 health launches advanced high precision large-scale aseptic syringe, cartridge and vial filling Line 2, supporting customers through commercial scale-up.

The clearances for relapsed/refractory B-ALL, aggressive B-NHL, and systemic lupus erythematosus (SLE) mark a major milestone in the global clinical development of META 10-19, built on the company’s pioneering META 10 metabolic reprogramming platform.

ten23 health and Ypsomed today announced the next milestone in their strategic partnership on the YpsoDose wearable injector: By installing dedicated device assembly capabilities for Ypsomed's large-volume wearable injector, ten23 health is further expanding the integrated development and manufacturing offering established by the two companies. The new equipment is now finalizing qualification.

Fast Track Designation granted for treatment of osteosarcoma Orphan Drug Designation granted for treatment of soft tissue sarcoma Multiple FDA designations underscores the promise of SOT106 and strengthens the program’s potential path to patients First-in-human study of SOT106 on track to be initiated in 2026